YIH
KYMR icon

Y-Intercept (HK)’s Kymera Therapeutics KYMR Stock Holding History

Y-Intercept (HK)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,429
Closed -$2.83M – 1834
2025
Q4 		$2.83M Buy
+36,429
New +$2.46M 0.06% 450
2024
Q2 		– Sell
-16,364
Closed -$658K – 1661
2024
Q1 		$658K Buy
+16,364
New +$586K 0.05% 571
2023
Q4 		– Sell
-25,476
Closed -$354K – 1461
2023
Q3 		$354K Buy
+25,476
New +$512K 0.03% 695

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Y-Intercept (HK)'s KYMR Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 36,429 shares — an estimated $2.83M sold.

Y-Intercept (HK) first reported a position in KYMR in Q3 2023 and held it in 3 quarters. The position peaked at $2.83M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Y-Intercept (HK) reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 36,429 Kymera Therapeutics shares in Q1 2026, an estimated $2.83M.
  • Y-Intercept (HK) first reported a position in Kymera Therapeutics in Q3 2023 and held it in 3 quarters.
  • Y-Intercept (HK)'s Kymera Therapeutics position peaked at $2.83M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.